NCT06994650
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Enrollment target: estimated 140 to confirmed 144
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jun 2025 to Aug 13, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The change of AHI form baseline after 52 weeks of treatment
Timeframe: 52 weeks
Secondary (4)
The percentage change in AHI from baseline after 52 weeks of treatment
The percentage of subjects with ≥50% AHI reduction from baseline after 52 weeks of treatment;
The percentage of subjects with AHI <5.0 events /h, or AHI ranging from 5.0 to 14.0 events/h and Epworth Sleepiness Scale (ESS) ≤10 after 52 weeks of treatment;
The percent change in body weight from baseline after 52 weeks of treatment.
Arms and interventions
HRS9531Experimental
PlaceboPlacebo comparator
Drugs: HRS9531, Placebo
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, Beijing Municipality, China